Hormonal contraception and replacement and the use of androgens in the antiphospholipid syndrome

Journal of Autoimmunity

Volumn 15, Issue 2, 2000, Pages 213-216

  Lahita, Robert G ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PRASTERONE; WARFARIN;

ANDROGEN THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING TIME; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG USE; ESTROGEN SYNTHESIS; FEMALE; FIBRINOLYSIS; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; NONHUMAN; PRIORITY JOURNAL; RAT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOGENESIS;

EID: 0033826261     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0428     Document Type: Conference Paper

References (41)

1. Oral contraceptives in systemic lupus erythematosus: Side effects and influence on the activity of SLE
2. Hormone replacement therapy in women with rheumatic disease
3. Systemic lupus erythematosus, antiphospholipid antibodies, chorea and oral contraceptives
4. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus
5. Sex steroids and SLE: Metabolism of androgens to estrogens
6. Estrogen metabolism in systemic lupus erythematosus: Patients and family members
7. Increased oxidation of testosterone in systemic lupus erythematosus
8. Low plasma androgens in women with systemic lupus erythematosus
9. Genetic regulation of drug metabolism and systemic lupus erythematosus
10. Estrogen-induced systemic lupus erythematosus
11. Oral contraceptives and systemic lupus erythematosus
12. Influence of oral contraceptive therapy on activity of systemic lupus erythematosus
13. Current use of estrogen replacement therapy in postmenopausal systemic lupus erythematosus patients: Increase since inception of the SELENA trial
14. Safety of hormone replacement therapy in postmenopausal patients with systemic lupus erythematosus
15. Antiphospholipid syndrome in pregnancy - Animal models and clinical implications
16. Animal models for antiphospholipid syndrome in pregnancy
17. Can women with systemic lupus erythematosus safely use exogenous estrogens?
18. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus
19. Hormone replacement therapy in systemic lupus erythematosus
20. Venous thromboembolic events associated with hormone replacement therapy
21. Hormone-replacement therapy and the risk of hospitalization for venous thromboembolism: A population based study in southern europe
22. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women
23. Oral contraceptives and hormone replacement therapy do not increase the incidence of arterial thrombosis in a no human primate model
24. Response to activated protein C during normal menstrual cycle and ovarian stimulation
25. Risk of thrombosis with oral contraceptives: Value of a thrombophilia screening test
26. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: Results from the estrogen in women with atherosclerosis study
27. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomized, placebo-controlled 12 year study
28. Coagulation activation following estrogen administration to postmenopausal women
29. A longitudinal study of the relationships between hemostatics, lipid and estradiol changes during normal human pregnancy
30. Sex differences in the anticoagulant effects of warfarin
31. Enhanced sensitivity of the extrinsic coagulation system during ovarian stimulation for in-vitro fertilization
32. Does ovarian Stimulation for in-vitro fertilization induce a hypercoagulable state?
33. Estrogen associated thromboembolism
34. Estrogen stimulates von Willebrand factor production by cultured endothelial cells
35. Oral contraception, circulatory immune complexes, anti ethinylestradiol antibodies and thrombosis
36. The reaction of 16-α hydroxyestrone with erythrocytes in vitro and in vivo
37. Formation of co-valent adducts between cortisol and 16-alpha-hydroxyestrone and protein, possible role in pathogenesis of cortisol toxicity and SLE
38. Nonenzymatic modification of red cell and lymphocyte membrane proteins by 16-alpha hydroxyestrone in patients with systemic lupus erythematosus
39. Anti-estrogen antibodies in users of oral contraceptives and in patients with systemic lupus erythematosus
40. Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of phospholipid antibodies
41. Effects of androgens on hemostasis